Skip to main content

11 - References

References

Drug treatment of other psychiatric conditions CHAPTER 9 References

  1. Raman SR, et al. Trends in attention-­deficit hyperactivity disorder medication use: a retrospective observational study using population-­based databases. Lancet Psychiatry 2018; 5:­824–­835.
  2. Piper BJ, et al. Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016. PLoS One 2018; 13:e0206100.
  3. NHS Business Services Authority. Medicines used in mental ­health –­ ­England –­ 2015/16 to 2022/23. 2023; https://www.nhsbsa.nhs.uk/ statistical-­collections/medicines-­used-­mental-­health-­england/medicines-­used-­mental-­health-­england-­201516-­202223.
  4. DIVA Foundation. DIVA-­5: Diagnostic Interview for ADHD in adults (DIVA). 2019 (last accessed December 2023); https://www.divacenter. eu/DIVA.aspx?id=461.
  5. National Institute for Health and Care Excellence. QbTest for the assessment of attention deficit hyperactivity disorder (ADHD). Medtech Innovation Briefing [MIB318]. 2023; https://www.nice.org.uk/advice/mib318.
  6. Shaw M, et al. A systematic review and analysis of long-­term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-­treatment. BMC Med 2012; 10:99.
  7. Boesen K, et al. Extended-­release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2022; 2:CD012857.
  8. Cândido RCF, et al. Immediate-­release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2021; 1:CD013011.
  9. Castells X, et  al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2018; 8:CD007813.
  10. Zhang L, et al. Risk of cardiovascular diseases associated with medications used in attention-­deficit/hyperactivity disorder: a systematic review and meta-­analysis. JAMA Network Open 2022; 5:e2243597.
  11. Zhang L, et al. Attention-­deficit/hyperactivity disorder medications and long-­term risk of cardiovascular diseases. JAMA Psychiatry 2024; 81:­178–­187.
  12. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE Guideline [NG87]. 2018 (last updated September 2019, last accessed December 2023); https://www.nice.org.uk/guidance/NG87.
  13. Viktorin A, et al. The risk of treatment-­emergent mania with methylphenidate in bipolar disorder. Am J Psychiatry 2017; 174:­341–­348.
  14. Radonjić NV, et al. Nonstimulant medications for attention-­deficit/hyperactivity disorder (ADHD) in adults: systematic review and meta-­analysis. CNS Drugs 2023; 37:­381–­397. Drug group Drug Advantages Disadvantages Non-­ stimulants Atomoxetine (NE reuptake inhibitor) Not Controlled ­Drugs –­ less restrictive prescribing regulations   Can help when stimulants are not indicated or not tolerated (e.g. tic disorders, active substance use disorders, others)   Might be considered by specialists in case of refractory ADHD or as an alternative to stimulants Require weeks to attain full effect   Higher risk of interactions (metabolised by CYP2D6) and effect variability due to ­genotype –­ might require dose adjustments26   Lower effect size than stimulants Guanfacine (α2A-adrenoceptor agonist) In many countries off-­label (unlicensed) for ADHD in adults   Off-­label prescribing may restrict opportunities to transfer to primary care. Viloxazine (5HT-­ and NE-­modulating agent) USA only Bupropion (dopamine and NE reuptake inhibitor) Limited evidence base 5HT, 5-­hydroxytryptamine; NE, norepinephrine. Table 9.1  (Continued )

802 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 9 15. Bolea-­Alamañac B, et al. Evidence-­based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2014; 28:­179–­203. 16. Cortese S, et al. Comparative efficacy and tolerability of medications for attention-­deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-­analysis. Lancet Psychiatry 2018; 5:­727–­738. 17. Heikkinen M, et al. Association of pharmacological treatments and hospitalization and death in individuals with amphetamine use disorders in a Swedish nationwide cohort of 13 965 patients. JAMA Psychiatry 2023; 80:­31–­39. 18. Cunill R, et al. Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta-­analysis and meta-­regression in over 9000 patients. Psychopharmacology (Berl) 2016; 233:­187–­197. 19. Crunelle CL, et al. International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit/hyperactivity disorder. Eur Addict Res 2018; 24:­43–­51. 20. Yu S, et al. Guanfacine for the treatment of attention-­deficit hyperactivity disorder: an updated systematic review and meta-­analysis. J Child Adolesc Psychopharmacol 2023; 33:­40–­50. 21. Nasser A, et al. A phase III, randomized, double-­blind, placebo-­controlled trial assessing the efficacy and safety of viloxazine extended-­release capsules in adults with attention-­deficit/hyperactivity disorder. CNS Drugs 2022; 36:­897–­915. 22. Verbeeck W, et al. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2017; 10:CD009504. 23. National Institute for Health and Care Excellence. Controlled drugs: safe use and management. NICE Guideline [NG46]. 2016 (last checked December 2023); https://www.nice.org.uk/guidance/ng46/chapter/context. 24. Gallagher CT, et al. Doctor or drug dealer? International legal provisions for the legitimate handling of drugs of abuse. Drug Sci Policy Law 2020; 6:2050324519900070. 25. General Medical Council. Controlled drugs and other medicines where additional safeguards are needed. 2021; https://www.gmc-­uk.org/ ethical-­guidance/ethical-­guidance-­for-­doctors/good-­practice-­in-­prescribing-­and-­managing-­medicines-­and-­devices/controlled- ­drugs-­and-­other-­medicines-­where-­additional-­safeguards-­are-­needed. 26. Clinical Pharmacogenetics Implementation Consortium (CPIC). CPIC® guideline for atomoxetine based on CYP2D6 genotype. 2019 (last checked December 2023); https://cpicpgx.org/guidelines/cpic-­guideline-­for-­atomoxetine-­based-­on-­cyp2d6-­genotype/.

No comments to display

Back to top